EP4593953A1 — Inhibition of luteinizing hormone (lh) action as treatment of perimenopausal and postmenopausal symptoms and complications
Assigned to Rigshospitalet · Expires 2025-08-06 · 1y expired
What this patent protects
The present invention is based on the realization and verification that inhibition of Luteinizing hormone (LH) and/or luteinizing hormone/ choriogonadotropin receptor (LHCGR) is useful in the treatment, alleviation or prevention of different medical states related to perimenopaus…
USPTO Abstract
The present invention is based on the realization and verification that inhibition of Luteinizing hormone (LH) and/or luteinizing hormone/ choriogonadotropin receptor (LHCGR) is useful in the treatment, alleviation or prevention of different medical states related to perimenopause and menopause in women or hypogonadism in men. Thus, an aspect of the present invention relates to LH and/ or LHCGR inhibitors for use in the treatment of postmenopausal osteoporosis in a female subject. Another aspect relates to LH and/or LHCGR inhibitors for use in the reduction of fat mass in a postmenopausal female subject. A further aspect relates to LH and/ or LHCGR inhibitors for use in the treatment, hypergonadotropic hypogonadism in a male subject. In addition, another aspect relates to LH and/or LHCGR inhibitors for use in the treatment of symptoms of perimenopause and/or postmenopause such as hot flashes, night sweats, osteoporosis, weight gain, hypothyroidism, conversion of T4 to T3, and/or primary hyperparathyroidism.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.